Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (471-480 of 520) with videos related to

Pageof 52
Sort By:
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of the American College of Cardiology|May 14, 2024
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level AnalysisJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF TrialHenri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
European Heart Journal|November 4, 2004
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registryEric J Velazquez, Gary S Francis, Paul W Armstrong, et al.
Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology|April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart FailureLi Shen, Pardeep S Jhund, Inder S Anand, et al.
Clinical Trials (London, England)|April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challengesThomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Pageof 52

Showing results (471-480 of 520) with videos related to

Sort By:
Pageof 52
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of the American College of Cardiology|May 14, 2024
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level AnalysisJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.
Circulation. Heart Failure|August 30, 2024
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF TrialHenri Lu, Safia Chatur, Sahmin Lee, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
European Heart Journal|November 4, 2004
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registryEric J Velazquez, Gary S Francis, Paul W Armstrong, et al.
Circulation. Heart Failure|December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trialSanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
Journal of the American College of Cardiology|April 23, 2021
Incidence and Outcomes of Pneumonia in Patients With Heart FailureLi Shen, Pardeep S Jhund, Inder S Anand, et al.
Clinical Trials (London, England)|April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challengesThomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Pageof 52